Global Nucleoside Antiviral Drugs Supply, Demand and Key Producers, 2026-2032
The global Nucleoside Antiviral Drugs market size is expected to reach $ 9669 million by 2032, rising at a market growth of 3.1% CAGR during the forecast period (2026-2032).
Nucleoside antiviral drugs are small-molecule therapeutics based on natural or structurally modified nucleoside analogues, acting primarily by interfering with viral nucleic acid replication or reverse transcriptase activity. They are mainly used for the treatment of HIV, hepatitis B, hepatitis C, herpesvirus, and cytomegalovirus infections. The primary dosage forms include tablets, capsules, oral solutions, and injectables. Key upstream materials include nucleobases, ribose or deoxyribose derivatives, chiral intermediates, protecting-group reagents, purified solvents, pharmaceutical excipients, and packaging materials. Downstream customers comprise global pharmaceutical companies, hospitals, public health procurement agencies, and chronic-treatment patient populations. On an ex-factory finished-dosage basis, the global nominal production capacity in 2025 is approximately 21.4 billion doses, with actual sales around 17.63 billion doses, an average ex-factory price of about US$0.43 per dose, and an industry gross margin ranging from 38% to 55%. Generic products typically have high turnover and lower prices, while innovative or patented products command higher unit prices and profitability.
The global nucleoside antiviral drugs market exhibits a relatively stable structure, with leading companies in North America and Japan dominating in research, development, and production capabilities, while small and medium-sized enterprises in China and India are gradually entering the market through licensed production and generic strategies to establish regional competitiveness. Demand is primarily driven by chronic viral infection patients, with long-term therapy ensuring steady consumption of core products, and supportive policies for innovative drug development and international registration provide a stable environment for growth. Market concentration is high, but generics and regional entrants create a multi-tiered competitive landscape, encouraging continuous optimization in research, pricing, and channel strategies.
Technological innovation serves as the primary driver for the industry's development, particularly in prodrug design, combination therapies, adaptation to resistant strains, and long-acting formulations. Companies enhance pharmacokinetics, improve patient adherence, and expand indications to achieve differentiated competition. This not only increases the market attractiveness of high-value originator drugs but also provides technology catch-up opportunities for generic manufacturers. In the future, with the emergence of new viruses and continuous improvement in chronic virus management protocols, innovation-driven research will remain the central market growth driver.
Market growth faces certain obstacles, including increased price competition following patent expirations, extended development timelines and clinical trial risks for new drugs, and regulatory approval uncertainties. Furthermore, the stability of key upstream materials, chiral intermediates, and protecting-group reagents poses challenges to continuous production. Regional policy variations, healthcare coverage, and patient access also affect market penetration, forcing companies to implement precise global planning, pricing, and production strategies.
Overall, the nucleoside antiviral drugs market continues to experience moderate growth, with long-term therapy demand and new indication expansion being the core drivers. Leading companies maintain dominance through R&D, production, and global distribution advantages, while smaller firms supplement the market through generics and regional products. The industry exhibits mature and stable characteristics, but innovation capability and differentiation strategies will determine future market positioning and profitability. Policy, patent management, and supply chain stability remain critical long-term considerations for all companies.
This report studies the global Nucleoside Antiviral Drugs production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Nucleoside Antiviral Drugs and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Nucleoside Antiviral Drugs that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Nucleoside Antiviral Drugs total production and demand, 2021-2032, (K Dose)
Global Nucleoside Antiviral Drugs total production value, 2021-2032, (USD Million)
Global Nucleoside Antiviral Drugs production by region & country, production, value, CAGR, 2021-2032, (USD Million) & (K Dose), (based on production site)
Global Nucleoside Antiviral Drugs consumption by region & country, CAGR, 2021-2032 & (K Dose)
U.S. VS China: Nucleoside Antiviral Drugs domestic production, consumption, key domestic manufacturers and share
Global Nucleoside Antiviral Drugs production by manufacturer, production, price, value and market share 2021-2026, (USD Million) & (K Dose)
Global Nucleoside Antiviral Drugs production by Type, production, value, CAGR, 2021-2032, (USD Million) & (K Dose)
Global Nucleoside Antiviral Drugs production by Application, production, value, CAGR, 2021-2032, (USD Million) & (K Dose)
This report profiles key players in the global Nucleoside Antiviral Drugs market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Gilead Sciences, Bristol-Myers Squibb, Merck & Co., Johnson & Johnson, AbbVie, Chugai Pharmaceutical, Takeda Pharmaceutical, Fosun Pharma, Shanghai Henlius, Hainan Poly Pharm, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Nucleoside Antiviral Drugs market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Dose) and average price (US$/Dose) by manufacturer, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Nucleoside Antiviral Drugs Market, By Region:
1. How big is the global Nucleoside Antiviral Drugs market?
2. What is the demand of the global Nucleoside Antiviral Drugs market?
3. What is the year over year growth of the global Nucleoside Antiviral Drugs market?
4. What is the production and production value of the global Nucleoside Antiviral Drugs market?
5. Who are the key producers in the global Nucleoside Antiviral Drugs market?
6. What are the growth factors driving the market demand?
Nucleoside antiviral drugs are small-molecule therapeutics based on natural or structurally modified nucleoside analogues, acting primarily by interfering with viral nucleic acid replication or reverse transcriptase activity. They are mainly used for the treatment of HIV, hepatitis B, hepatitis C, herpesvirus, and cytomegalovirus infections. The primary dosage forms include tablets, capsules, oral solutions, and injectables. Key upstream materials include nucleobases, ribose or deoxyribose derivatives, chiral intermediates, protecting-group reagents, purified solvents, pharmaceutical excipients, and packaging materials. Downstream customers comprise global pharmaceutical companies, hospitals, public health procurement agencies, and chronic-treatment patient populations. On an ex-factory finished-dosage basis, the global nominal production capacity in 2025 is approximately 21.4 billion doses, with actual sales around 17.63 billion doses, an average ex-factory price of about US$0.43 per dose, and an industry gross margin ranging from 38% to 55%. Generic products typically have high turnover and lower prices, while innovative or patented products command higher unit prices and profitability.
The global nucleoside antiviral drugs market exhibits a relatively stable structure, with leading companies in North America and Japan dominating in research, development, and production capabilities, while small and medium-sized enterprises in China and India are gradually entering the market through licensed production and generic strategies to establish regional competitiveness. Demand is primarily driven by chronic viral infection patients, with long-term therapy ensuring steady consumption of core products, and supportive policies for innovative drug development and international registration provide a stable environment for growth. Market concentration is high, but generics and regional entrants create a multi-tiered competitive landscape, encouraging continuous optimization in research, pricing, and channel strategies.
Technological innovation serves as the primary driver for the industry's development, particularly in prodrug design, combination therapies, adaptation to resistant strains, and long-acting formulations. Companies enhance pharmacokinetics, improve patient adherence, and expand indications to achieve differentiated competition. This not only increases the market attractiveness of high-value originator drugs but also provides technology catch-up opportunities for generic manufacturers. In the future, with the emergence of new viruses and continuous improvement in chronic virus management protocols, innovation-driven research will remain the central market growth driver.
Market growth faces certain obstacles, including increased price competition following patent expirations, extended development timelines and clinical trial risks for new drugs, and regulatory approval uncertainties. Furthermore, the stability of key upstream materials, chiral intermediates, and protecting-group reagents poses challenges to continuous production. Regional policy variations, healthcare coverage, and patient access also affect market penetration, forcing companies to implement precise global planning, pricing, and production strategies.
Overall, the nucleoside antiviral drugs market continues to experience moderate growth, with long-term therapy demand and new indication expansion being the core drivers. Leading companies maintain dominance through R&D, production, and global distribution advantages, while smaller firms supplement the market through generics and regional products. The industry exhibits mature and stable characteristics, but innovation capability and differentiation strategies will determine future market positioning and profitability. Policy, patent management, and supply chain stability remain critical long-term considerations for all companies.
This report studies the global Nucleoside Antiviral Drugs production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Nucleoside Antiviral Drugs and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Nucleoside Antiviral Drugs that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Nucleoside Antiviral Drugs total production and demand, 2021-2032, (K Dose)
Global Nucleoside Antiviral Drugs total production value, 2021-2032, (USD Million)
Global Nucleoside Antiviral Drugs production by region & country, production, value, CAGR, 2021-2032, (USD Million) & (K Dose), (based on production site)
Global Nucleoside Antiviral Drugs consumption by region & country, CAGR, 2021-2032 & (K Dose)
U.S. VS China: Nucleoside Antiviral Drugs domestic production, consumption, key domestic manufacturers and share
Global Nucleoside Antiviral Drugs production by manufacturer, production, price, value and market share 2021-2026, (USD Million) & (K Dose)
Global Nucleoside Antiviral Drugs production by Type, production, value, CAGR, 2021-2032, (USD Million) & (K Dose)
Global Nucleoside Antiviral Drugs production by Application, production, value, CAGR, 2021-2032, (USD Million) & (K Dose)
This report profiles key players in the global Nucleoside Antiviral Drugs market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Gilead Sciences, Bristol-Myers Squibb, Merck & Co., Johnson & Johnson, AbbVie, Chugai Pharmaceutical, Takeda Pharmaceutical, Fosun Pharma, Shanghai Henlius, Hainan Poly Pharm, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Nucleoside Antiviral Drugs market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Dose) and average price (US$/Dose) by manufacturer, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Nucleoside Antiviral Drugs Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- Tenofovir Alafenamide
- Emtricitabine
- Tenofovir Disoproxil Fumarate
- Entecavir
- Sofosbuvir
- Other
- Oral Solid Dosage Forms
- Oral Liquid Dosage Forms
- Injectable Dosage Forms
- Originator Drugs
- Generic Drugs
- Hospital
- Clinic
- Other
- Gilead Sciences
- Bristol-Myers Squibb
- Merck & Co.
- Johnson & Johnson
- AbbVie
- Chugai Pharmaceutical
- Takeda Pharmaceutical
- Fosun Pharma
- Shanghai Henlius
- Hainan Poly Pharm
- BioNTech
- Roche
- Teva Pharmaceutical
- Cipla
- Sun Pharmaceutical
- Viatris
1. How big is the global Nucleoside Antiviral Drugs market?
2. What is the demand of the global Nucleoside Antiviral Drugs market?
3. What is the year over year growth of the global Nucleoside Antiviral Drugs market?
4. What is the production and production value of the global Nucleoside Antiviral Drugs market?
5. Who are the key producers in the global Nucleoside Antiviral Drugs market?
6. What are the growth factors driving the market demand?
1 SUPPLY SUMMARY
1.1 Nucleoside Antiviral Drugs Introduction
1.2 World Nucleoside Antiviral Drugs Supply & Forecast
1.2.1 World Nucleoside Antiviral Drugs Production Value (2021 & 2025 & 2032)
1.2.2 World Nucleoside Antiviral Drugs Production (2021-2032)
1.2.3 World Nucleoside Antiviral Drugs Pricing Trends (2021-2032)
1.3 World Nucleoside Antiviral Drugs Production by Region (Based on Production Site)
1.3.1 World Nucleoside Antiviral Drugs Production Value by Region (2021-2032)
1.3.2 World Nucleoside Antiviral Drugs Production by Region (2021-2032)
1.3.3 World Nucleoside Antiviral Drugs Average Price by Region (2021-2032)
1.3.4 North America Nucleoside Antiviral Drugs Production (2021-2032)
1.3.5 Europe Nucleoside Antiviral Drugs Production (2021-2032)
1.3.6 China Nucleoside Antiviral Drugs Production (2021-2032)
1.3.7 Japan Nucleoside Antiviral Drugs Production (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Nucleoside Antiviral Drugs Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Nucleoside Antiviral Drugs Major Market Trends
2 DEMAND SUMMARY
2.1 World Nucleoside Antiviral Drugs Demand (2021-2032)
2.2 World Nucleoside Antiviral Drugs Consumption by Region
2.2.1 World Nucleoside Antiviral Drugs Consumption by Region (2021-2026)
2.2.2 World Nucleoside Antiviral Drugs Consumption Forecast by Region (2027-2032)
2.3 United States Nucleoside Antiviral Drugs Consumption (2021-2032)
2.4 China Nucleoside Antiviral Drugs Consumption (2021-2032)
2.5 Europe Nucleoside Antiviral Drugs Consumption (2021-2032)
2.6 Japan Nucleoside Antiviral Drugs Consumption (2021-2032)
2.7 South Korea Nucleoside Antiviral Drugs Consumption (2021-2032)
2.8 ASEAN Nucleoside Antiviral Drugs Consumption (2021-2032)
2.9 India Nucleoside Antiviral Drugs Consumption (2021-2032)
3 WORLD MANUFACTURERS COMPETITIVE ANALYSIS
3.1 World Nucleoside Antiviral Drugs Production Value by Manufacturer (2021-2026)
3.2 World Nucleoside Antiviral Drugs Production by Manufacturer (2021-2026)
3.3 World Nucleoside Antiviral Drugs Average Price by Manufacturer (2021-2026)
3.4 Nucleoside Antiviral Drugs Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global Nucleoside Antiviral Drugs Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for Nucleoside Antiviral Drugs in 2025
3.5.3 Global Concentration Ratios (CR8) for Nucleoside Antiviral Drugs in 2025
3.6 Nucleoside Antiviral Drugs Market: Overall Company Footprint Analysis
3.6.1 Nucleoside Antiviral Drugs Market: Region Footprint
3.6.2 Nucleoside Antiviral Drugs Market: Company Product Type Footprint
3.6.3 Nucleoside Antiviral Drugs Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 UNITED STATES VS CHINA VS REST OF THE WORLD
4.1 United States VS China: Nucleoside Antiviral Drugs Production Value Comparison
4.1.1 United States VS China: Nucleoside Antiviral Drugs Production Value Comparison (2021 & 2025 & 2032)
4.1.2 United States VS China: Nucleoside Antiviral Drugs Production Value Market Share Comparison (2021 & 2025 & 2032)
4.2 United States VS China: Nucleoside Antiviral Drugs Production Comparison
4.2.1 United States VS China: Nucleoside Antiviral Drugs Production Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Nucleoside Antiviral Drugs Production Market Share Comparison (2021 & 2025 & 2032)
4.3 United States VS China: Nucleoside Antiviral Drugs Consumption Comparison
4.3.1 United States VS China: Nucleoside Antiviral Drugs Consumption Comparison (2021 & 2025 & 2032)
4.3.2 United States VS China: Nucleoside Antiviral Drugs Consumption Market Share Comparison (2021 & 2025 & 2032)
4.4 United States Based Nucleoside Antiviral Drugs Manufacturers and Market Share, 2021-2026
4.4.1 United States Based Nucleoside Antiviral Drugs Manufacturers, Headquarters and Production Site (States, Country)
4.4.2 United States Based Manufacturers Nucleoside Antiviral Drugs Production Value (2021-2026)
4.4.3 United States Based Manufacturers Nucleoside Antiviral Drugs Production (2021-2026)
4.5 China Based Nucleoside Antiviral Drugs Manufacturers and Market Share
4.5.1 China Based Nucleoside Antiviral Drugs Manufacturers, Headquarters and Production Site (Province, Country)
4.5.2 China Based Manufacturers Nucleoside Antiviral Drugs Production Value (2021-2026)
4.5.3 China Based Manufacturers Nucleoside Antiviral Drugs Production (2021-2026)
4.6 Rest of World Based Nucleoside Antiviral Drugs Manufacturers and Market Share, 2021-2026
4.6.1 Rest of World Based Nucleoside Antiviral Drugs Manufacturers, Headquarters and Production Site (State, Country)
4.6.2 Rest of World Based Manufacturers Nucleoside Antiviral Drugs Production Value (2021-2026)
4.6.3 Rest of World Based Manufacturers Nucleoside Antiviral Drugs Production (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World Nucleoside Antiviral Drugs Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 Tenofovir Alafenamide
5.2.2 Emtricitabine
5.2.3 Tenofovir Disoproxil Fumarate
5.2.4 Entecavir
5.2.5 Sofosbuvir
5.2.6 Other
5.3 Market Segment by Type
5.3.1 World Nucleoside Antiviral Drugs Production by Type (2021-2032)
5.3.2 World Nucleoside Antiviral Drugs Production Value by Type (2021-2032)
5.3.3 World Nucleoside Antiviral Drugs Average Price by Type (2021-2032)
6 MARKET ANALYSIS BY DOSAGE FORM
6.1 World Nucleoside Antiviral Drugs Market Size Overview by Dosage Form: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Dosage Form
6.2.1 Oral Solid Dosage Forms
6.2.2 Oral Liquid Dosage Forms
6.2.3 Injectable Dosage Forms
6.3 Market Segment by Dosage Form
6.3.1 World Nucleoside Antiviral Drugs Production by Dosage Form (2021-2032)
6.3.2 World Nucleoside Antiviral Drugs Production Value by Dosage Form (2021-2032)
6.3.3 World Nucleoside Antiviral Drugs Average Price by Dosage Form (2021-2032)
7 MARKET ANALYSIS BY COMMERCIALIZATION STATUS
7.1 World Nucleoside Antiviral Drugs Market Size Overview by Commercialization Status: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Commercialization Status
7.2.1 Originator Drugs
7.2.2 Generic Drugs
7.3 Market Segment by Commercialization Status
7.3.1 World Nucleoside Antiviral Drugs Production by Commercialization Status (2021-2032)
7.3.2 World Nucleoside Antiviral Drugs Production Value by Commercialization Status (2021-2032)
7.3.3 World Nucleoside Antiviral Drugs Average Price by Commercialization Status (2021-2032)
8 MARKET ANALYSIS BY APPLICATION
8.1 World Nucleoside Antiviral Drugs Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
8.2.1 Hospital
8.2.2 Clinic
8.2.3 Other
8.3 Market Segment by Application
8.3.1 World Nucleoside Antiviral Drugs Production by Application (2021-2032)
8.3.2 World Nucleoside Antiviral Drugs Production Value by Application (2021-2032)
8.3.3 World Nucleoside Antiviral Drugs Average Price by Application (2021-2032)
9 COMPANY PROFILES
9.1 Gilead Sciences
9.1.1 Gilead Sciences Details
9.1.2 Gilead Sciences Major Business
9.1.3 Gilead Sciences Nucleoside Antiviral Drugs Product and Services
9.1.4 Gilead Sciences Nucleoside Antiviral Drugs Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.1.5 Gilead Sciences Recent Developments/Updates
9.1.6 Gilead Sciences Competitive Strengths & Weaknesses
9.2 Bristol-Myers Squibb
9.2.1 Bristol-Myers Squibb Details
9.2.2 Bristol-Myers Squibb Major Business
9.2.3 Bristol-Myers Squibb Nucleoside Antiviral Drugs Product and Services
9.2.4 Bristol-Myers Squibb Nucleoside Antiviral Drugs Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.2.5 Bristol-Myers Squibb Recent Developments/Updates
9.2.6 Bristol-Myers Squibb Competitive Strengths & Weaknesses
9.3 Merck & Co.
9.3.1 Merck & Co. Details
9.3.2 Merck & Co. Major Business
9.3.3 Merck & Co. Nucleoside Antiviral Drugs Product and Services
9.3.4 Merck & Co. Nucleoside Antiviral Drugs Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.3.5 Merck & Co. Recent Developments/Updates
9.3.6 Merck & Co. Competitive Strengths & Weaknesses
9.4 Johnson & Johnson
9.4.1 Johnson & Johnson Details
9.4.2 Johnson & Johnson Major Business
9.4.3 Johnson & Johnson Nucleoside Antiviral Drugs Product and Services
9.4.4 Johnson & Johnson Nucleoside Antiviral Drugs Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.4.5 Johnson & Johnson Recent Developments/Updates
9.4.6 Johnson & Johnson Competitive Strengths & Weaknesses
9.5 AbbVie
9.5.1 AbbVie Details
9.5.2 AbbVie Major Business
9.5.3 AbbVie Nucleoside Antiviral Drugs Product and Services
9.5.4 AbbVie Nucleoside Antiviral Drugs Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.5.5 AbbVie Recent Developments/Updates
9.5.6 AbbVie Competitive Strengths & Weaknesses
9.6 Chugai Pharmaceutical
9.6.1 Chugai Pharmaceutical Details
9.6.2 Chugai Pharmaceutical Major Business
9.6.3 Chugai Pharmaceutical Nucleoside Antiviral Drugs Product and Services
9.6.4 Chugai Pharmaceutical Nucleoside Antiviral Drugs Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.6.5 Chugai Pharmaceutical Recent Developments/Updates
9.6.6 Chugai Pharmaceutical Competitive Strengths & Weaknesses
9.7 Takeda Pharmaceutical
9.7.1 Takeda Pharmaceutical Details
9.7.2 Takeda Pharmaceutical Major Business
9.7.3 Takeda Pharmaceutical Nucleoside Antiviral Drugs Product and Services
9.7.4 Takeda Pharmaceutical Nucleoside Antiviral Drugs Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.7.5 Takeda Pharmaceutical Recent Developments/Updates
9.7.6 Takeda Pharmaceutical Competitive Strengths & Weaknesses
9.8 Fosun Pharma
9.8.1 Fosun Pharma Details
9.8.2 Fosun Pharma Major Business
9.8.3 Fosun Pharma Nucleoside Antiviral Drugs Product and Services
9.8.4 Fosun Pharma Nucleoside Antiviral Drugs Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.8.5 Fosun Pharma Recent Developments/Updates
9.8.6 Fosun Pharma Competitive Strengths & Weaknesses
9.9 Shanghai Henlius
9.9.1 Shanghai Henlius Details
9.9.2 Shanghai Henlius Major Business
9.9.3 Shanghai Henlius Nucleoside Antiviral Drugs Product and Services
9.9.4 Shanghai Henlius Nucleoside Antiviral Drugs Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.9.5 Shanghai Henlius Recent Developments/Updates
9.9.6 Shanghai Henlius Competitive Strengths & Weaknesses
9.10 Hainan Poly Pharm
9.10.1 Hainan Poly Pharm Details
9.10.2 Hainan Poly Pharm Major Business
9.10.3 Hainan Poly Pharm Nucleoside Antiviral Drugs Product and Services
9.10.4 Hainan Poly Pharm Nucleoside Antiviral Drugs Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.10.5 Hainan Poly Pharm Recent Developments/Updates
9.10.6 Hainan Poly Pharm Competitive Strengths & Weaknesses
9.11 BioNTech
9.11.1 BioNTech Details
9.11.2 BioNTech Major Business
9.11.3 BioNTech Nucleoside Antiviral Drugs Product and Services
9.11.4 BioNTech Nucleoside Antiviral Drugs Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.11.5 BioNTech Recent Developments/Updates
9.11.6 BioNTech Competitive Strengths & Weaknesses
9.12 Roche
9.12.1 Roche Details
9.12.2 Roche Major Business
9.12.3 Roche Nucleoside Antiviral Drugs Product and Services
9.12.4 Roche Nucleoside Antiviral Drugs Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.12.5 Roche Recent Developments/Updates
9.12.6 Roche Competitive Strengths & Weaknesses
9.13 Teva Pharmaceutical
9.13.1 Teva Pharmaceutical Details
9.13.2 Teva Pharmaceutical Major Business
9.13.3 Teva Pharmaceutical Nucleoside Antiviral Drugs Product and Services
9.13.4 Teva Pharmaceutical Nucleoside Antiviral Drugs Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.13.5 Teva Pharmaceutical Recent Developments/Updates
9.13.6 Teva Pharmaceutical Competitive Strengths & Weaknesses
9.14 Cipla
9.14.1 Cipla Details
9.14.2 Cipla Major Business
9.14.3 Cipla Nucleoside Antiviral Drugs Product and Services
9.14.4 Cipla Nucleoside Antiviral Drugs Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.14.5 Cipla Recent Developments/Updates
9.14.6 Cipla Competitive Strengths & Weaknesses
9.15 Sun Pharmaceutical
9.15.1 Sun Pharmaceutical Details
9.15.2 Sun Pharmaceutical Major Business
9.15.3 Sun Pharmaceutical Nucleoside Antiviral Drugs Product and Services
9.15.4 Sun Pharmaceutical Nucleoside Antiviral Drugs Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.15.5 Sun Pharmaceutical Recent Developments/Updates
9.15.6 Sun Pharmaceutical Competitive Strengths & Weaknesses
9.16 Viatris
9.16.1 Viatris Details
9.16.2 Viatris Major Business
9.16.3 Viatris Nucleoside Antiviral Drugs Product and Services
9.16.4 Viatris Nucleoside Antiviral Drugs Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.16.5 Viatris Recent Developments/Updates
9.16.6 Viatris Competitive Strengths & Weaknesses
10 INDUSTRY CHAIN ANALYSIS
10.1 Nucleoside Antiviral Drugs Industry Chain
10.2 Nucleoside Antiviral Drugs Upstream Analysis
10.2.1 Nucleoside Antiviral Drugs Core Raw Materials
10.2.2 Main Manufacturers of Nucleoside Antiviral Drugs Core Raw Materials
10.3 Midstream Analysis
10.4 Downstream Analysis
10.5 Nucleoside Antiviral Drugs Production Mode
10.6 Nucleoside Antiviral Drugs Procurement Model
10.7 Nucleoside Antiviral Drugs Industry Sales Model and Sales Channels
10.7.1 Nucleoside Antiviral Drugs Sales Model
10.7.2 Nucleoside Antiviral Drugs Typical Distributors
11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
1.1 Nucleoside Antiviral Drugs Introduction
1.2 World Nucleoside Antiviral Drugs Supply & Forecast
1.2.1 World Nucleoside Antiviral Drugs Production Value (2021 & 2025 & 2032)
1.2.2 World Nucleoside Antiviral Drugs Production (2021-2032)
1.2.3 World Nucleoside Antiviral Drugs Pricing Trends (2021-2032)
1.3 World Nucleoside Antiviral Drugs Production by Region (Based on Production Site)
1.3.1 World Nucleoside Antiviral Drugs Production Value by Region (2021-2032)
1.3.2 World Nucleoside Antiviral Drugs Production by Region (2021-2032)
1.3.3 World Nucleoside Antiviral Drugs Average Price by Region (2021-2032)
1.3.4 North America Nucleoside Antiviral Drugs Production (2021-2032)
1.3.5 Europe Nucleoside Antiviral Drugs Production (2021-2032)
1.3.6 China Nucleoside Antiviral Drugs Production (2021-2032)
1.3.7 Japan Nucleoside Antiviral Drugs Production (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Nucleoside Antiviral Drugs Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Nucleoside Antiviral Drugs Major Market Trends
2 DEMAND SUMMARY
2.1 World Nucleoside Antiviral Drugs Demand (2021-2032)
2.2 World Nucleoside Antiviral Drugs Consumption by Region
2.2.1 World Nucleoside Antiviral Drugs Consumption by Region (2021-2026)
2.2.2 World Nucleoside Antiviral Drugs Consumption Forecast by Region (2027-2032)
2.3 United States Nucleoside Antiviral Drugs Consumption (2021-2032)
2.4 China Nucleoside Antiviral Drugs Consumption (2021-2032)
2.5 Europe Nucleoside Antiviral Drugs Consumption (2021-2032)
2.6 Japan Nucleoside Antiviral Drugs Consumption (2021-2032)
2.7 South Korea Nucleoside Antiviral Drugs Consumption (2021-2032)
2.8 ASEAN Nucleoside Antiviral Drugs Consumption (2021-2032)
2.9 India Nucleoside Antiviral Drugs Consumption (2021-2032)
3 WORLD MANUFACTURERS COMPETITIVE ANALYSIS
3.1 World Nucleoside Antiviral Drugs Production Value by Manufacturer (2021-2026)
3.2 World Nucleoside Antiviral Drugs Production by Manufacturer (2021-2026)
3.3 World Nucleoside Antiviral Drugs Average Price by Manufacturer (2021-2026)
3.4 Nucleoside Antiviral Drugs Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global Nucleoside Antiviral Drugs Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for Nucleoside Antiviral Drugs in 2025
3.5.3 Global Concentration Ratios (CR8) for Nucleoside Antiviral Drugs in 2025
3.6 Nucleoside Antiviral Drugs Market: Overall Company Footprint Analysis
3.6.1 Nucleoside Antiviral Drugs Market: Region Footprint
3.6.2 Nucleoside Antiviral Drugs Market: Company Product Type Footprint
3.6.3 Nucleoside Antiviral Drugs Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 UNITED STATES VS CHINA VS REST OF THE WORLD
4.1 United States VS China: Nucleoside Antiviral Drugs Production Value Comparison
4.1.1 United States VS China: Nucleoside Antiviral Drugs Production Value Comparison (2021 & 2025 & 2032)
4.1.2 United States VS China: Nucleoside Antiviral Drugs Production Value Market Share Comparison (2021 & 2025 & 2032)
4.2 United States VS China: Nucleoside Antiviral Drugs Production Comparison
4.2.1 United States VS China: Nucleoside Antiviral Drugs Production Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Nucleoside Antiviral Drugs Production Market Share Comparison (2021 & 2025 & 2032)
4.3 United States VS China: Nucleoside Antiviral Drugs Consumption Comparison
4.3.1 United States VS China: Nucleoside Antiviral Drugs Consumption Comparison (2021 & 2025 & 2032)
4.3.2 United States VS China: Nucleoside Antiviral Drugs Consumption Market Share Comparison (2021 & 2025 & 2032)
4.4 United States Based Nucleoside Antiviral Drugs Manufacturers and Market Share, 2021-2026
4.4.1 United States Based Nucleoside Antiviral Drugs Manufacturers, Headquarters and Production Site (States, Country)
4.4.2 United States Based Manufacturers Nucleoside Antiviral Drugs Production Value (2021-2026)
4.4.3 United States Based Manufacturers Nucleoside Antiviral Drugs Production (2021-2026)
4.5 China Based Nucleoside Antiviral Drugs Manufacturers and Market Share
4.5.1 China Based Nucleoside Antiviral Drugs Manufacturers, Headquarters and Production Site (Province, Country)
4.5.2 China Based Manufacturers Nucleoside Antiviral Drugs Production Value (2021-2026)
4.5.3 China Based Manufacturers Nucleoside Antiviral Drugs Production (2021-2026)
4.6 Rest of World Based Nucleoside Antiviral Drugs Manufacturers and Market Share, 2021-2026
4.6.1 Rest of World Based Nucleoside Antiviral Drugs Manufacturers, Headquarters and Production Site (State, Country)
4.6.2 Rest of World Based Manufacturers Nucleoside Antiviral Drugs Production Value (2021-2026)
4.6.3 Rest of World Based Manufacturers Nucleoside Antiviral Drugs Production (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World Nucleoside Antiviral Drugs Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 Tenofovir Alafenamide
5.2.2 Emtricitabine
5.2.3 Tenofovir Disoproxil Fumarate
5.2.4 Entecavir
5.2.5 Sofosbuvir
5.2.6 Other
5.3 Market Segment by Type
5.3.1 World Nucleoside Antiviral Drugs Production by Type (2021-2032)
5.3.2 World Nucleoside Antiviral Drugs Production Value by Type (2021-2032)
5.3.3 World Nucleoside Antiviral Drugs Average Price by Type (2021-2032)
6 MARKET ANALYSIS BY DOSAGE FORM
6.1 World Nucleoside Antiviral Drugs Market Size Overview by Dosage Form: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Dosage Form
6.2.1 Oral Solid Dosage Forms
6.2.2 Oral Liquid Dosage Forms
6.2.3 Injectable Dosage Forms
6.3 Market Segment by Dosage Form
6.3.1 World Nucleoside Antiviral Drugs Production by Dosage Form (2021-2032)
6.3.2 World Nucleoside Antiviral Drugs Production Value by Dosage Form (2021-2032)
6.3.3 World Nucleoside Antiviral Drugs Average Price by Dosage Form (2021-2032)
7 MARKET ANALYSIS BY COMMERCIALIZATION STATUS
7.1 World Nucleoside Antiviral Drugs Market Size Overview by Commercialization Status: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Commercialization Status
7.2.1 Originator Drugs
7.2.2 Generic Drugs
7.3 Market Segment by Commercialization Status
7.3.1 World Nucleoside Antiviral Drugs Production by Commercialization Status (2021-2032)
7.3.2 World Nucleoside Antiviral Drugs Production Value by Commercialization Status (2021-2032)
7.3.3 World Nucleoside Antiviral Drugs Average Price by Commercialization Status (2021-2032)
8 MARKET ANALYSIS BY APPLICATION
8.1 World Nucleoside Antiviral Drugs Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
8.2.1 Hospital
8.2.2 Clinic
8.2.3 Other
8.3 Market Segment by Application
8.3.1 World Nucleoside Antiviral Drugs Production by Application (2021-2032)
8.3.2 World Nucleoside Antiviral Drugs Production Value by Application (2021-2032)
8.3.3 World Nucleoside Antiviral Drugs Average Price by Application (2021-2032)
9 COMPANY PROFILES
9.1 Gilead Sciences
9.1.1 Gilead Sciences Details
9.1.2 Gilead Sciences Major Business
9.1.3 Gilead Sciences Nucleoside Antiviral Drugs Product and Services
9.1.4 Gilead Sciences Nucleoside Antiviral Drugs Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.1.5 Gilead Sciences Recent Developments/Updates
9.1.6 Gilead Sciences Competitive Strengths & Weaknesses
9.2 Bristol-Myers Squibb
9.2.1 Bristol-Myers Squibb Details
9.2.2 Bristol-Myers Squibb Major Business
9.2.3 Bristol-Myers Squibb Nucleoside Antiviral Drugs Product and Services
9.2.4 Bristol-Myers Squibb Nucleoside Antiviral Drugs Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.2.5 Bristol-Myers Squibb Recent Developments/Updates
9.2.6 Bristol-Myers Squibb Competitive Strengths & Weaknesses
9.3 Merck & Co.
9.3.1 Merck & Co. Details
9.3.2 Merck & Co. Major Business
9.3.3 Merck & Co. Nucleoside Antiviral Drugs Product and Services
9.3.4 Merck & Co. Nucleoside Antiviral Drugs Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.3.5 Merck & Co. Recent Developments/Updates
9.3.6 Merck & Co. Competitive Strengths & Weaknesses
9.4 Johnson & Johnson
9.4.1 Johnson & Johnson Details
9.4.2 Johnson & Johnson Major Business
9.4.3 Johnson & Johnson Nucleoside Antiviral Drugs Product and Services
9.4.4 Johnson & Johnson Nucleoside Antiviral Drugs Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.4.5 Johnson & Johnson Recent Developments/Updates
9.4.6 Johnson & Johnson Competitive Strengths & Weaknesses
9.5 AbbVie
9.5.1 AbbVie Details
9.5.2 AbbVie Major Business
9.5.3 AbbVie Nucleoside Antiviral Drugs Product and Services
9.5.4 AbbVie Nucleoside Antiviral Drugs Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.5.5 AbbVie Recent Developments/Updates
9.5.6 AbbVie Competitive Strengths & Weaknesses
9.6 Chugai Pharmaceutical
9.6.1 Chugai Pharmaceutical Details
9.6.2 Chugai Pharmaceutical Major Business
9.6.3 Chugai Pharmaceutical Nucleoside Antiviral Drugs Product and Services
9.6.4 Chugai Pharmaceutical Nucleoside Antiviral Drugs Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.6.5 Chugai Pharmaceutical Recent Developments/Updates
9.6.6 Chugai Pharmaceutical Competitive Strengths & Weaknesses
9.7 Takeda Pharmaceutical
9.7.1 Takeda Pharmaceutical Details
9.7.2 Takeda Pharmaceutical Major Business
9.7.3 Takeda Pharmaceutical Nucleoside Antiviral Drugs Product and Services
9.7.4 Takeda Pharmaceutical Nucleoside Antiviral Drugs Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.7.5 Takeda Pharmaceutical Recent Developments/Updates
9.7.6 Takeda Pharmaceutical Competitive Strengths & Weaknesses
9.8 Fosun Pharma
9.8.1 Fosun Pharma Details
9.8.2 Fosun Pharma Major Business
9.8.3 Fosun Pharma Nucleoside Antiviral Drugs Product and Services
9.8.4 Fosun Pharma Nucleoside Antiviral Drugs Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.8.5 Fosun Pharma Recent Developments/Updates
9.8.6 Fosun Pharma Competitive Strengths & Weaknesses
9.9 Shanghai Henlius
9.9.1 Shanghai Henlius Details
9.9.2 Shanghai Henlius Major Business
9.9.3 Shanghai Henlius Nucleoside Antiviral Drugs Product and Services
9.9.4 Shanghai Henlius Nucleoside Antiviral Drugs Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.9.5 Shanghai Henlius Recent Developments/Updates
9.9.6 Shanghai Henlius Competitive Strengths & Weaknesses
9.10 Hainan Poly Pharm
9.10.1 Hainan Poly Pharm Details
9.10.2 Hainan Poly Pharm Major Business
9.10.3 Hainan Poly Pharm Nucleoside Antiviral Drugs Product and Services
9.10.4 Hainan Poly Pharm Nucleoside Antiviral Drugs Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.10.5 Hainan Poly Pharm Recent Developments/Updates
9.10.6 Hainan Poly Pharm Competitive Strengths & Weaknesses
9.11 BioNTech
9.11.1 BioNTech Details
9.11.2 BioNTech Major Business
9.11.3 BioNTech Nucleoside Antiviral Drugs Product and Services
9.11.4 BioNTech Nucleoside Antiviral Drugs Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.11.5 BioNTech Recent Developments/Updates
9.11.6 BioNTech Competitive Strengths & Weaknesses
9.12 Roche
9.12.1 Roche Details
9.12.2 Roche Major Business
9.12.3 Roche Nucleoside Antiviral Drugs Product and Services
9.12.4 Roche Nucleoside Antiviral Drugs Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.12.5 Roche Recent Developments/Updates
9.12.6 Roche Competitive Strengths & Weaknesses
9.13 Teva Pharmaceutical
9.13.1 Teva Pharmaceutical Details
9.13.2 Teva Pharmaceutical Major Business
9.13.3 Teva Pharmaceutical Nucleoside Antiviral Drugs Product and Services
9.13.4 Teva Pharmaceutical Nucleoside Antiviral Drugs Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.13.5 Teva Pharmaceutical Recent Developments/Updates
9.13.6 Teva Pharmaceutical Competitive Strengths & Weaknesses
9.14 Cipla
9.14.1 Cipla Details
9.14.2 Cipla Major Business
9.14.3 Cipla Nucleoside Antiviral Drugs Product and Services
9.14.4 Cipla Nucleoside Antiviral Drugs Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.14.5 Cipla Recent Developments/Updates
9.14.6 Cipla Competitive Strengths & Weaknesses
9.15 Sun Pharmaceutical
9.15.1 Sun Pharmaceutical Details
9.15.2 Sun Pharmaceutical Major Business
9.15.3 Sun Pharmaceutical Nucleoside Antiviral Drugs Product and Services
9.15.4 Sun Pharmaceutical Nucleoside Antiviral Drugs Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.15.5 Sun Pharmaceutical Recent Developments/Updates
9.15.6 Sun Pharmaceutical Competitive Strengths & Weaknesses
9.16 Viatris
9.16.1 Viatris Details
9.16.2 Viatris Major Business
9.16.3 Viatris Nucleoside Antiviral Drugs Product and Services
9.16.4 Viatris Nucleoside Antiviral Drugs Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.16.5 Viatris Recent Developments/Updates
9.16.6 Viatris Competitive Strengths & Weaknesses
10 INDUSTRY CHAIN ANALYSIS
10.1 Nucleoside Antiviral Drugs Industry Chain
10.2 Nucleoside Antiviral Drugs Upstream Analysis
10.2.1 Nucleoside Antiviral Drugs Core Raw Materials
10.2.2 Main Manufacturers of Nucleoside Antiviral Drugs Core Raw Materials
10.3 Midstream Analysis
10.4 Downstream Analysis
10.5 Nucleoside Antiviral Drugs Production Mode
10.6 Nucleoside Antiviral Drugs Procurement Model
10.7 Nucleoside Antiviral Drugs Industry Sales Model and Sales Channels
10.7.1 Nucleoside Antiviral Drugs Sales Model
10.7.2 Nucleoside Antiviral Drugs Typical Distributors
11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
LIST OF TABLES
Table 1. World Nucleoside Antiviral Drugs Production Value by Region (2021, 2025 and 2032) & (USD Million)
Table 2. World Nucleoside Antiviral Drugs Production Value by Region (2021-2026) & (USD Million)
Table 3. World Nucleoside Antiviral Drugs Production Value by Region (2027-2032) & (USD Million)
Table 4. World Nucleoside Antiviral Drugs Production Value Market Share by Region (2021-2026)
Table 5. World Nucleoside Antiviral Drugs Production Value Market Share by Region (2027-2032)
Table 6. World Nucleoside Antiviral Drugs Production by Region (2021-2026) & (K Dose)
Table 7. World Nucleoside Antiviral Drugs Production by Region (2027-2032) & (K Dose)
Table 8. World Nucleoside Antiviral Drugs Production Market Share by Region (2021-2026)
Table 9. World Nucleoside Antiviral Drugs Production Market Share by Region (2027-2032)
Table 10. World Nucleoside Antiviral Drugs Average Price by Region (2021-2026) & (US$/Dose)
Table 11. World Nucleoside Antiviral Drugs Average Price by Region (2027-2032) & (US$/Dose)
Table 12. Nucleoside Antiviral Drugs Major Market Trends
Table 13. World Nucleoside Antiviral Drugs Consumption Growth Rate Forecast by Region (2021 & 2025 & 2032) & (K Dose)
Table 14. World Nucleoside Antiviral Drugs Consumption by Region (2021-2026) & (K Dose)
Table 15. World Nucleoside Antiviral Drugs Consumption Forecast by Region (2027-2032) & (K Dose)
Table 16. World Nucleoside Antiviral Drugs Production Value by Manufacturer (2021-2026) & (USD Million)
Table 17. Production Value Market Share of Key Nucleoside Antiviral Drugs Producers in 2025
Table 18. World Nucleoside Antiviral Drugs Production by Manufacturer (2021-2026) & (K Dose)
Table 19. Production Market Share of Key Nucleoside Antiviral Drugs Producers in 2025
Table 20. World Nucleoside Antiviral Drugs Average Price by Manufacturer (2021-2026) & (US$/Dose)
Table 21. Global Nucleoside Antiviral Drugs Company Evaluation Quadrant
Table 22. World Nucleoside Antiviral Drugs Industry Rank of Major Manufacturers, Based on Production Value in 2025
Table 23. Head Office and Nucleoside Antiviral Drugs Production Site of Key Manufacturer
Table 24. Nucleoside Antiviral Drugs Market: Company Product Type Footprint
Table 25. Nucleoside Antiviral Drugs Market: Company Product Application Footprint
Table 26. Nucleoside Antiviral Drugs Competitive Factors
Table 27. Nucleoside Antiviral Drugs New Entrant and Capacity Expansion Plans
Table 28. Nucleoside Antiviral Drugs Mergers & Acquisitions Activity
Table 29. United States VS China Nucleoside Antiviral Drugs Production Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 30. United States VS China Nucleoside Antiviral Drugs Production Comparison, (2021 & 2025 & 2032) & (K Dose)
Table 31. United States VS China Nucleoside Antiviral Drugs Consumption Comparison, (2021 & 2025 & 2032) & (K Dose)
Table 32. United States Based Nucleoside Antiviral Drugs Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers Nucleoside Antiviral Drugs Production Value, (2021-2026) & (USD Million)
Table 34. United States Based Manufacturers Nucleoside Antiviral Drugs Production Value Market Share (2021-2026)
Table 35. United States Based Manufacturers Nucleoside Antiviral Drugs Production (2021-2026) & (K Dose)
Table 36. United States Based Manufacturers Nucleoside Antiviral Drugs Production Market Share (2021-2026)
Table 37. China Based Nucleoside Antiviral Drugs Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers Nucleoside Antiviral Drugs Production Value, (2021-2026) & (USD Million)
Table 39. China Based Manufacturers Nucleoside Antiviral Drugs Production Value Market Share (2021-2026)
Table 40. China Based Manufacturers Nucleoside Antiviral Drugs Production, (2021-2026) & (K Dose)
Table 41. China Based Manufacturers Nucleoside Antiviral Drugs Production Market Share (2021-2026)
Table 42. Rest of World Based Nucleoside Antiviral Drugs Manufacturers, Headquarters and Production Site (State, Country)
Table 43. Rest of World Based Manufacturers Nucleoside Antiviral Drugs Production Value, (2021-2026) & (USD Million)
Table 44. Rest of World Based Manufacturers Nucleoside Antiviral Drugs Production Value Market Share (2021-2026)
Table 45. Rest of World Based Manufacturers Nucleoside Antiviral Drugs Production, (2021-2026) & (K Dose)
Table 46. Rest of World Based Manufacturers Nucleoside Antiviral Drugs Production Market Share (2021-2026)
Table 47. World Nucleoside Antiviral Drugs Production Value by Type, (USD Million), 2021 & 2025 & 2032
Table 48. World Nucleoside Antiviral Drugs Production by Type (2021-2026) & (K Dose)
Table 49. World Nucleoside Antiviral Drugs Production by Type (2027-2032) & (K Dose)
Table 50. World Nucleoside Antiviral Drugs Production Value by Type (2021-2026) & (USD Million)
Table 51. World Nucleoside Antiviral Drugs Production Value by Type (2027-2032) & (USD Million)
Table 52. World Nucleoside Antiviral Drugs Average Price by Type (2021-2026) & (US$/Dose)
Table 53. World Nucleoside Antiviral Drugs Average Price by Type (2027-2032) & (US$/Dose)
Table 54. World Nucleoside Antiviral Drugs Production Value by Dosage Form, (USD Million), 2021 & 2025 & 2032
Table 55. World Nucleoside Antiviral Drugs Production by Dosage Form (2021-2026) & (K Dose)
Table 56. World Nucleoside Antiviral Drugs Production by Dosage Form (2027-2032) & (K Dose)
Table 57. World Nucleoside Antiviral Drugs Production Value by Dosage Form (2021-2026) & (USD Million)
Table 58. World Nucleoside Antiviral Drugs Production Value by Dosage Form (2027-2032) & (USD Million)
Table 59. World Nucleoside Antiviral Drugs Average Price by Dosage Form (2021-2026) & (US$/Dose)
Table 60. World Nucleoside Antiviral Drugs Average Price by Dosage Form (2027-2032) & (US$/Dose)
Table 61. World Nucleoside Antiviral Drugs Production Value by Commercialization Status, (USD Million), 2021 & 2025 & 2032
Table 62. World Nucleoside Antiviral Drugs Production by Commercialization Status (2021-2026) & (K Dose)
Table 63. World Nucleoside Antiviral Drugs Production by Commercialization Status (2027-2032) & (K Dose)
Table 64. World Nucleoside Antiviral Drugs Production Value by Commercialization Status (2021-2026) & (USD Million)
Table 65. World Nucleoside Antiviral Drugs Production Value by Commercialization Status (2027-2032) & (USD Million)
Table 66. World Nucleoside Antiviral Drugs Average Price by Commercialization Status (2021-2026) & (US$/Dose)
Table 67. World Nucleoside Antiviral Drugs Average Price by Commercialization Status (2027-2032) & (US$/Dose)
Table 68. World Nucleoside Antiviral Drugs Production Value by Application, (USD Million), 2021 & 2025 & 2032
Table 69. World Nucleoside Antiviral Drugs Production by Application (2021-2026) & (K Dose)
Table 70. World Nucleoside Antiviral Drugs Production by Application (2027-2032) & (K Dose)
Table 71. World Nucleoside Antiviral Drugs Production Value by Application (2021-2026) & (USD Million)
Table 72. World Nucleoside Antiviral Drugs Production Value by Application (2027-2032) & (USD Million)
Table 73. World Nucleoside Antiviral Drugs Average Price by Application (2021-2026) & (US$/Dose)
Table 74. World Nucleoside Antiviral Drugs Average Price by Application (2027-2032) & (US$/Dose)
Table 75. Gilead Sciences Basic Information, Manufacturing Base and Competitors
Table 76. Gilead Sciences Major Business
Table 77. Gilead Sciences Nucleoside Antiviral Drugs Product and Services
Table 78. Gilead Sciences Nucleoside Antiviral Drugs Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 79. Gilead Sciences Recent Developments/Updates
Table 80. Gilead Sciences Competitive Strengths & Weaknesses
Table 81. Bristol-Myers Squibb Basic Information, Manufacturing Base and Competitors
Table 82. Bristol-Myers Squibb Major Business
Table 83. Bristol-Myers Squibb Nucleoside Antiviral Drugs Product and Services
Table 84. Bristol-Myers Squibb Nucleoside Antiviral Drugs Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 85. Bristol-Myers Squibb Recent Developments/Updates
Table 86. Bristol-Myers Squibb Competitive Strengths & Weaknesses
Table 87. Merck & Co. Basic Information, Manufacturing Base and Competitors
Table 88. Merck & Co. Major Business
Table 89. Merck & Co. Nucleoside Antiviral Drugs Product and Services
Table 90. Merck & Co. Nucleoside Antiviral Drugs Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 91. Merck & Co. Recent Developments/Updates
Table 92. Merck & Co. Competitive Strengths & Weaknesses
Table 93. Johnson & Johnson Basic Information, Manufacturing Base and Competitors
Table 94. Johnson & Johnson Major Business
Table 95. Johnson & Johnson Nucleoside Antiviral Drugs Product and Services
Table 96. Johnson & Johnson Nucleoside Antiviral Drugs Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 97. Johnson & Johnson Recent Developments/Updates
Table 98. Johnson & Johnson Competitive Strengths & Weaknesses
Table 99. AbbVie Basic Information, Manufacturing Base and Competitors
Table 100. AbbVie Major Business
Table 101. AbbVie Nucleoside Antiviral Drugs Product and Services
Table 102. AbbVie Nucleoside Antiviral Drugs Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 103. AbbVie Recent Developments/Updates
Table 104. AbbVie Competitive Strengths & Weaknesses
Table 105. Chugai Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 106. Chugai Pharmaceutical Major Business
Table 107. Chugai Pharmaceutical Nucleoside Antiviral Drugs Product and Services
Table 108. Chugai Pharmaceutical Nucleoside Antiviral Drugs Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 109. Chugai Pharmaceutical Recent Developments/Updates
Table 110. Chugai Pharmaceutical Competitive Strengths & Weaknesses
Table 111. Takeda Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 112. Takeda Pharmaceutical Major Business
Table 113. Takeda Pharmaceutical Nucleoside Antiviral Drugs Product and Services
Table 114. Takeda Pharmaceutical Nucleoside Antiviral Drugs Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 115. Takeda Pharmaceutical Recent Developments/Updates
Table 116. Takeda Pharmaceutical Competitive Strengths & Weaknesses
Table 117. Fosun Pharma Basic Information, Manufacturing Base and Competitors
Table 118. Fosun Pharma Major Business
Table 119. Fosun Pharma Nucleoside Antiviral Drugs Product and Services
Table 120. Fosun Pharma Nucleoside Antiviral Drugs Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 121. Fosun Pharma Recent Developments/Updates
Table 122. Fosun Pharma Competitive Strengths & Weaknesses
Table 123. Shanghai Henlius Basic Information, Manufacturing Base and Competitors
Table 124. Shanghai Henlius Major Business
Table 125. Shanghai Henlius Nucleoside Antiviral Drugs Product and Services
Table 126. Shanghai Henlius Nucleoside Antiviral Drugs Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 127. Shanghai Henlius Recent Developments/Updates
Table 128. Shanghai Henlius Competitive Strengths & Weaknesses
Table 129. Hainan Poly Pharm Basic Information, Manufacturing Base and Competitors
Table 130. Hainan Poly Pharm Major Business
Table 131. Hainan Poly Pharm Nucleoside Antiviral Drugs Product and Services
Table 132. Hainan Poly Pharm Nucleoside Antiviral Drugs Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 133. Hainan Poly Pharm Recent Developments/Updates
Table 134. Hainan Poly Pharm Competitive Strengths & Weaknesses
Table 135. BioNTech Basic Information, Manufacturing Base and Competitors
Table 136. BioNTech Major Business
Table 137. BioNTech Nucleoside Antiviral Drugs Product and Services
Table 138. BioNTech Nucleoside Antiviral Drugs Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 139. BioNTech Recent Developments/Updates
Table 140. BioNTech Competitive Strengths & Weaknesses
Table 141. Roche Basic Information, Manufacturing Base and Competitors
Table 142. Roche Major Business
Table 143. Roche Nucleoside Antiviral Drugs Product and Services
Table 144. Roche Nucleoside Antiviral Drugs Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 145. Roche Recent Developments/Updates
Table 146. Roche Competitive Strengths & Weaknesses
Table 147. Teva Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 148. Teva Pharmaceutical Major Business
Table 149. Teva Pharmaceutical Nucleoside Antiviral Drugs Product and Services
Table 150. Teva Pharmaceutical Nucleoside Antiviral Drugs Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 151. Teva Pharmaceutical Recent Developments/Updates
Table 152. Teva Pharmaceutical Competitive Strengths & Weaknesses
Table 153. Cipla Basic Information, Manufacturing Base and Competitors
Table 154. Cipla Major Business
Table 155. Cipla Nucleoside Antiviral Drugs Product and Services
Table 156. Cipla Nucleoside Antiviral Drugs Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 157. Cipla Recent Developments/Updates
Table 158. Cipla Competitive Strengths & Weaknesses
Table 159. Sun Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 160. Sun Pharmaceutical Major Business
Table 161. Sun Pharmaceutical Nucleoside Antiviral Drugs Product and Services
Table 162. Sun Pharmaceutical Nucleoside Antiviral Drugs Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 163. Sun Pharmaceutical Recent Developments/Updates
Table 164. Sun Pharmaceutical Competitive Strengths & Weaknesses
Table 165. Viatris Basic Information, Manufacturing Base and Competitors
Table 166. Viatris Major Business
Table 167. Viatris Nucleoside Antiviral Drugs Product and Services
Table 168. Viatris Nucleoside Antiviral Drugs Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 169. Viatris Recent Developments/Updates
Table 170. Viatris Competitive Strengths & Weaknesses
Table 171. Global Key Players of Nucleoside Antiviral Drugs Upstream (Raw Materials)
Table 172. Global Nucleoside Antiviral Drugs Typical Customers
Table 173. Nucleoside Antiviral Drugs Typical Distributors
Table 1. World Nucleoside Antiviral Drugs Production Value by Region (2021, 2025 and 2032) & (USD Million)
Table 2. World Nucleoside Antiviral Drugs Production Value by Region (2021-2026) & (USD Million)
Table 3. World Nucleoside Antiviral Drugs Production Value by Region (2027-2032) & (USD Million)
Table 4. World Nucleoside Antiviral Drugs Production Value Market Share by Region (2021-2026)
Table 5. World Nucleoside Antiviral Drugs Production Value Market Share by Region (2027-2032)
Table 6. World Nucleoside Antiviral Drugs Production by Region (2021-2026) & (K Dose)
Table 7. World Nucleoside Antiviral Drugs Production by Region (2027-2032) & (K Dose)
Table 8. World Nucleoside Antiviral Drugs Production Market Share by Region (2021-2026)
Table 9. World Nucleoside Antiviral Drugs Production Market Share by Region (2027-2032)
Table 10. World Nucleoside Antiviral Drugs Average Price by Region (2021-2026) & (US$/Dose)
Table 11. World Nucleoside Antiviral Drugs Average Price by Region (2027-2032) & (US$/Dose)
Table 12. Nucleoside Antiviral Drugs Major Market Trends
Table 13. World Nucleoside Antiviral Drugs Consumption Growth Rate Forecast by Region (2021 & 2025 & 2032) & (K Dose)
Table 14. World Nucleoside Antiviral Drugs Consumption by Region (2021-2026) & (K Dose)
Table 15. World Nucleoside Antiviral Drugs Consumption Forecast by Region (2027-2032) & (K Dose)
Table 16. World Nucleoside Antiviral Drugs Production Value by Manufacturer (2021-2026) & (USD Million)
Table 17. Production Value Market Share of Key Nucleoside Antiviral Drugs Producers in 2025
Table 18. World Nucleoside Antiviral Drugs Production by Manufacturer (2021-2026) & (K Dose)
Table 19. Production Market Share of Key Nucleoside Antiviral Drugs Producers in 2025
Table 20. World Nucleoside Antiviral Drugs Average Price by Manufacturer (2021-2026) & (US$/Dose)
Table 21. Global Nucleoside Antiviral Drugs Company Evaluation Quadrant
Table 22. World Nucleoside Antiviral Drugs Industry Rank of Major Manufacturers, Based on Production Value in 2025
Table 23. Head Office and Nucleoside Antiviral Drugs Production Site of Key Manufacturer
Table 24. Nucleoside Antiviral Drugs Market: Company Product Type Footprint
Table 25. Nucleoside Antiviral Drugs Market: Company Product Application Footprint
Table 26. Nucleoside Antiviral Drugs Competitive Factors
Table 27. Nucleoside Antiviral Drugs New Entrant and Capacity Expansion Plans
Table 28. Nucleoside Antiviral Drugs Mergers & Acquisitions Activity
Table 29. United States VS China Nucleoside Antiviral Drugs Production Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 30. United States VS China Nucleoside Antiviral Drugs Production Comparison, (2021 & 2025 & 2032) & (K Dose)
Table 31. United States VS China Nucleoside Antiviral Drugs Consumption Comparison, (2021 & 2025 & 2032) & (K Dose)
Table 32. United States Based Nucleoside Antiviral Drugs Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers Nucleoside Antiviral Drugs Production Value, (2021-2026) & (USD Million)
Table 34. United States Based Manufacturers Nucleoside Antiviral Drugs Production Value Market Share (2021-2026)
Table 35. United States Based Manufacturers Nucleoside Antiviral Drugs Production (2021-2026) & (K Dose)
Table 36. United States Based Manufacturers Nucleoside Antiviral Drugs Production Market Share (2021-2026)
Table 37. China Based Nucleoside Antiviral Drugs Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers Nucleoside Antiviral Drugs Production Value, (2021-2026) & (USD Million)
Table 39. China Based Manufacturers Nucleoside Antiviral Drugs Production Value Market Share (2021-2026)
Table 40. China Based Manufacturers Nucleoside Antiviral Drugs Production, (2021-2026) & (K Dose)
Table 41. China Based Manufacturers Nucleoside Antiviral Drugs Production Market Share (2021-2026)
Table 42. Rest of World Based Nucleoside Antiviral Drugs Manufacturers, Headquarters and Production Site (State, Country)
Table 43. Rest of World Based Manufacturers Nucleoside Antiviral Drugs Production Value, (2021-2026) & (USD Million)
Table 44. Rest of World Based Manufacturers Nucleoside Antiviral Drugs Production Value Market Share (2021-2026)
Table 45. Rest of World Based Manufacturers Nucleoside Antiviral Drugs Production, (2021-2026) & (K Dose)
Table 46. Rest of World Based Manufacturers Nucleoside Antiviral Drugs Production Market Share (2021-2026)
Table 47. World Nucleoside Antiviral Drugs Production Value by Type, (USD Million), 2021 & 2025 & 2032
Table 48. World Nucleoside Antiviral Drugs Production by Type (2021-2026) & (K Dose)
Table 49. World Nucleoside Antiviral Drugs Production by Type (2027-2032) & (K Dose)
Table 50. World Nucleoside Antiviral Drugs Production Value by Type (2021-2026) & (USD Million)
Table 51. World Nucleoside Antiviral Drugs Production Value by Type (2027-2032) & (USD Million)
Table 52. World Nucleoside Antiviral Drugs Average Price by Type (2021-2026) & (US$/Dose)
Table 53. World Nucleoside Antiviral Drugs Average Price by Type (2027-2032) & (US$/Dose)
Table 54. World Nucleoside Antiviral Drugs Production Value by Dosage Form, (USD Million), 2021 & 2025 & 2032
Table 55. World Nucleoside Antiviral Drugs Production by Dosage Form (2021-2026) & (K Dose)
Table 56. World Nucleoside Antiviral Drugs Production by Dosage Form (2027-2032) & (K Dose)
Table 57. World Nucleoside Antiviral Drugs Production Value by Dosage Form (2021-2026) & (USD Million)
Table 58. World Nucleoside Antiviral Drugs Production Value by Dosage Form (2027-2032) & (USD Million)
Table 59. World Nucleoside Antiviral Drugs Average Price by Dosage Form (2021-2026) & (US$/Dose)
Table 60. World Nucleoside Antiviral Drugs Average Price by Dosage Form (2027-2032) & (US$/Dose)
Table 61. World Nucleoside Antiviral Drugs Production Value by Commercialization Status, (USD Million), 2021 & 2025 & 2032
Table 62. World Nucleoside Antiviral Drugs Production by Commercialization Status (2021-2026) & (K Dose)
Table 63. World Nucleoside Antiviral Drugs Production by Commercialization Status (2027-2032) & (K Dose)
Table 64. World Nucleoside Antiviral Drugs Production Value by Commercialization Status (2021-2026) & (USD Million)
Table 65. World Nucleoside Antiviral Drugs Production Value by Commercialization Status (2027-2032) & (USD Million)
Table 66. World Nucleoside Antiviral Drugs Average Price by Commercialization Status (2021-2026) & (US$/Dose)
Table 67. World Nucleoside Antiviral Drugs Average Price by Commercialization Status (2027-2032) & (US$/Dose)
Table 68. World Nucleoside Antiviral Drugs Production Value by Application, (USD Million), 2021 & 2025 & 2032
Table 69. World Nucleoside Antiviral Drugs Production by Application (2021-2026) & (K Dose)
Table 70. World Nucleoside Antiviral Drugs Production by Application (2027-2032) & (K Dose)
Table 71. World Nucleoside Antiviral Drugs Production Value by Application (2021-2026) & (USD Million)
Table 72. World Nucleoside Antiviral Drugs Production Value by Application (2027-2032) & (USD Million)
Table 73. World Nucleoside Antiviral Drugs Average Price by Application (2021-2026) & (US$/Dose)
Table 74. World Nucleoside Antiviral Drugs Average Price by Application (2027-2032) & (US$/Dose)
Table 75. Gilead Sciences Basic Information, Manufacturing Base and Competitors
Table 76. Gilead Sciences Major Business
Table 77. Gilead Sciences Nucleoside Antiviral Drugs Product and Services
Table 78. Gilead Sciences Nucleoside Antiviral Drugs Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 79. Gilead Sciences Recent Developments/Updates
Table 80. Gilead Sciences Competitive Strengths & Weaknesses
Table 81. Bristol-Myers Squibb Basic Information, Manufacturing Base and Competitors
Table 82. Bristol-Myers Squibb Major Business
Table 83. Bristol-Myers Squibb Nucleoside Antiviral Drugs Product and Services
Table 84. Bristol-Myers Squibb Nucleoside Antiviral Drugs Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 85. Bristol-Myers Squibb Recent Developments/Updates
Table 86. Bristol-Myers Squibb Competitive Strengths & Weaknesses
Table 87. Merck & Co. Basic Information, Manufacturing Base and Competitors
Table 88. Merck & Co. Major Business
Table 89. Merck & Co. Nucleoside Antiviral Drugs Product and Services
Table 90. Merck & Co. Nucleoside Antiviral Drugs Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 91. Merck & Co. Recent Developments/Updates
Table 92. Merck & Co. Competitive Strengths & Weaknesses
Table 93. Johnson & Johnson Basic Information, Manufacturing Base and Competitors
Table 94. Johnson & Johnson Major Business
Table 95. Johnson & Johnson Nucleoside Antiviral Drugs Product and Services
Table 96. Johnson & Johnson Nucleoside Antiviral Drugs Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 97. Johnson & Johnson Recent Developments/Updates
Table 98. Johnson & Johnson Competitive Strengths & Weaknesses
Table 99. AbbVie Basic Information, Manufacturing Base and Competitors
Table 100. AbbVie Major Business
Table 101. AbbVie Nucleoside Antiviral Drugs Product and Services
Table 102. AbbVie Nucleoside Antiviral Drugs Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 103. AbbVie Recent Developments/Updates
Table 104. AbbVie Competitive Strengths & Weaknesses
Table 105. Chugai Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 106. Chugai Pharmaceutical Major Business
Table 107. Chugai Pharmaceutical Nucleoside Antiviral Drugs Product and Services
Table 108. Chugai Pharmaceutical Nucleoside Antiviral Drugs Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 109. Chugai Pharmaceutical Recent Developments/Updates
Table 110. Chugai Pharmaceutical Competitive Strengths & Weaknesses
Table 111. Takeda Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 112. Takeda Pharmaceutical Major Business
Table 113. Takeda Pharmaceutical Nucleoside Antiviral Drugs Product and Services
Table 114. Takeda Pharmaceutical Nucleoside Antiviral Drugs Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 115. Takeda Pharmaceutical Recent Developments/Updates
Table 116. Takeda Pharmaceutical Competitive Strengths & Weaknesses
Table 117. Fosun Pharma Basic Information, Manufacturing Base and Competitors
Table 118. Fosun Pharma Major Business
Table 119. Fosun Pharma Nucleoside Antiviral Drugs Product and Services
Table 120. Fosun Pharma Nucleoside Antiviral Drugs Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 121. Fosun Pharma Recent Developments/Updates
Table 122. Fosun Pharma Competitive Strengths & Weaknesses
Table 123. Shanghai Henlius Basic Information, Manufacturing Base and Competitors
Table 124. Shanghai Henlius Major Business
Table 125. Shanghai Henlius Nucleoside Antiviral Drugs Product and Services
Table 126. Shanghai Henlius Nucleoside Antiviral Drugs Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 127. Shanghai Henlius Recent Developments/Updates
Table 128. Shanghai Henlius Competitive Strengths & Weaknesses
Table 129. Hainan Poly Pharm Basic Information, Manufacturing Base and Competitors
Table 130. Hainan Poly Pharm Major Business
Table 131. Hainan Poly Pharm Nucleoside Antiviral Drugs Product and Services
Table 132. Hainan Poly Pharm Nucleoside Antiviral Drugs Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 133. Hainan Poly Pharm Recent Developments/Updates
Table 134. Hainan Poly Pharm Competitive Strengths & Weaknesses
Table 135. BioNTech Basic Information, Manufacturing Base and Competitors
Table 136. BioNTech Major Business
Table 137. BioNTech Nucleoside Antiviral Drugs Product and Services
Table 138. BioNTech Nucleoside Antiviral Drugs Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 139. BioNTech Recent Developments/Updates
Table 140. BioNTech Competitive Strengths & Weaknesses
Table 141. Roche Basic Information, Manufacturing Base and Competitors
Table 142. Roche Major Business
Table 143. Roche Nucleoside Antiviral Drugs Product and Services
Table 144. Roche Nucleoside Antiviral Drugs Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 145. Roche Recent Developments/Updates
Table 146. Roche Competitive Strengths & Weaknesses
Table 147. Teva Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 148. Teva Pharmaceutical Major Business
Table 149. Teva Pharmaceutical Nucleoside Antiviral Drugs Product and Services
Table 150. Teva Pharmaceutical Nucleoside Antiviral Drugs Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 151. Teva Pharmaceutical Recent Developments/Updates
Table 152. Teva Pharmaceutical Competitive Strengths & Weaknesses
Table 153. Cipla Basic Information, Manufacturing Base and Competitors
Table 154. Cipla Major Business
Table 155. Cipla Nucleoside Antiviral Drugs Product and Services
Table 156. Cipla Nucleoside Antiviral Drugs Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 157. Cipla Recent Developments/Updates
Table 158. Cipla Competitive Strengths & Weaknesses
Table 159. Sun Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 160. Sun Pharmaceutical Major Business
Table 161. Sun Pharmaceutical Nucleoside Antiviral Drugs Product and Services
Table 162. Sun Pharmaceutical Nucleoside Antiviral Drugs Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 163. Sun Pharmaceutical Recent Developments/Updates
Table 164. Sun Pharmaceutical Competitive Strengths & Weaknesses
Table 165. Viatris Basic Information, Manufacturing Base and Competitors
Table 166. Viatris Major Business
Table 167. Viatris Nucleoside Antiviral Drugs Product and Services
Table 168. Viatris Nucleoside Antiviral Drugs Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 169. Viatris Recent Developments/Updates
Table 170. Viatris Competitive Strengths & Weaknesses
Table 171. Global Key Players of Nucleoside Antiviral Drugs Upstream (Raw Materials)
Table 172. Global Nucleoside Antiviral Drugs Typical Customers
Table 173. Nucleoside Antiviral Drugs Typical Distributors
LIST OF FIGURES
Figure 1. Nucleoside Antiviral Drugs Picture
Figure 2. World Nucleoside Antiviral Drugs Production Value: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Nucleoside Antiviral Drugs Production Value and Forecast (2021-2032) & (USD Million)
Figure 4. World Nucleoside Antiviral Drugs Production (2021-2032) & (K Dose)
Figure 5. World Nucleoside Antiviral Drugs Average Price (2021-2032) & (US$/Dose)
Figure 6. World Nucleoside Antiviral Drugs Production Value Market Share by Region (2021-2032)
Figure 7. World Nucleoside Antiviral Drugs Production Market Share by Region (2021-2032)
Figure 8. North America Nucleoside Antiviral Drugs Production (2021-2032) & (K Dose)
Figure 9. Europe Nucleoside Antiviral Drugs Production (2021-2032) & (K Dose)
Figure 10. China Nucleoside Antiviral Drugs Production (2021-2032) & (K Dose)
Figure 11. Japan Nucleoside Antiviral Drugs Production (2021-2032) & (K Dose)
Figure 12. Nucleoside Antiviral Drugs Market Drivers
Figure 13. Factors Affecting Demand
Figure 14. World Nucleoside Antiviral Drugs Consumption (2021-2032) & (K Dose)
Figure 15. World Nucleoside Antiviral Drugs Consumption Market Share by Region (2021-2032)
Figure 16. United States Nucleoside Antiviral Drugs Consumption (2021-2032) & (K Dose)
Figure 17. China Nucleoside Antiviral Drugs Consumption (2021-2032) & (K Dose)
Figure 18. Europe Nucleoside Antiviral Drugs Consumption (2021-2032) & (K Dose)
Figure 19. Japan Nucleoside Antiviral Drugs Consumption (2021-2032) & (K Dose)
Figure 20. South Korea Nucleoside Antiviral Drugs Consumption (2021-2032) & (K Dose)
Figure 21. ASEAN Nucleoside Antiviral Drugs Consumption (2021-2032) & (K Dose)
Figure 22. India Nucleoside Antiviral Drugs Consumption (2021-2032) & (K Dose)
Figure 23. Producer Shipments of Nucleoside Antiviral Drugs by Manufacturer Revenue ($MM) and Market Share (%): 2025
Figure 24. Global Four-firm Concentration Ratios (CR4) for Nucleoside Antiviral Drugs Markets in 2025
Figure 25. Global Four-firm Concentration Ratios (CR8) for Nucleoside Antiviral Drugs Markets in 2025
Figure 26. United States VS China: Nucleoside Antiviral Drugs Production Value Market Share Comparison (2021 & 2025 & 2032)
Figure 27. United States VS China: Nucleoside Antiviral Drugs Production Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Nucleoside Antiviral Drugs Consumption Market Share Comparison (2021 & 2025 & 2032)
Figure 29. United States Based Manufacturers Nucleoside Antiviral Drugs Production Market Share 2025
Figure 30. China Based Manufacturers Nucleoside Antiviral Drugs Production Market Share 2025
Figure 31. Rest of World Based Manufacturers Nucleoside Antiviral Drugs Production Market Share 2025
Figure 32. World Nucleoside Antiviral Drugs Production Value by Type, (USD Million), 2021 & 2025 & 2032
Figure 33. World Nucleoside Antiviral Drugs Production Value Market Share by Type in 2025
Figure 34. Tenofovir Alafenamide
Figure 35. Emtricitabine
Figure 36. Tenofovir Disoproxil Fumarate
Figure 37. Entecavir
Figure 38. Sofosbuvir
Figure 39. Other
Figure 40. World Nucleoside Antiviral Drugs Production Market Share by Type (2021-2032)
Figure 41. World Nucleoside Antiviral Drugs Production Value Market Share by Type (2021-2032)
Figure 42. World Nucleoside Antiviral Drugs Average Price by Type (2021-2032) & (US$/Dose)
Figure 43. World Nucleoside Antiviral Drugs Production Value by Dosage Form, (USD Million), 2021 & 2025 & 2032
Figure 44. World Nucleoside Antiviral Drugs Production Value Market Share by Dosage Form in 2025
Figure 45. Oral Solid Dosage Forms
Figure 46. Oral Liquid Dosage Forms
Figure 47. Injectable Dosage Forms
Figure 48. World Nucleoside Antiviral Drugs Production Market Share by Dosage Form (2021-2032)
Figure 49. World Nucleoside Antiviral Drugs Production Value Market Share by Dosage Form (2021-2032)
Figure 50. World Nucleoside Antiviral Drugs Average Price by Dosage Form (2021-2032) & (US$/Dose)
Figure 51. World Nucleoside Antiviral Drugs Production Value by Commercialization Status, (USD Million), 2021 & 2025 & 2032
Figure 52. World Nucleoside Antiviral Drugs Production Value Market Share by Commercialization Status in 2025
Figure 53. Originator Drugs
Figure 54. Generic Drugs
Figure 55. World Nucleoside Antiviral Drugs Production Market Share by Commercialization Status (2021-2032)
Figure 56. World Nucleoside Antiviral Drugs Production Value Market Share by Commercialization Status (2021-2032)
Figure 57. World Nucleoside Antiviral Drugs Average Price by Commercialization Status (2021-2032) & (US$/Dose)
Figure 58. World Nucleoside Antiviral Drugs Production Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 59. World Nucleoside Antiviral Drugs Production Value Market Share by Application in 2025
Figure 60. Hospital
Figure 61. Clinic
Figure 62. Other
Figure 63. World Nucleoside Antiviral Drugs Production Market Share by Application (2021-2032)
Figure 64. World Nucleoside Antiviral Drugs Production Value Market Share by Application (2021-2032)
Figure 65. World Nucleoside Antiviral Drugs Average Price by Application (2021-2032) & (US$/Dose)
Figure 66. Nucleoside Antiviral Drugs Industry Chain
Figure 67. Nucleoside Antiviral Drugs Procurement Model
Figure 68. Nucleoside Antiviral Drugs Sales Model
Figure 69. Nucleoside Antiviral Drugs Sales Channels, Direct Sales, and Distribution
Figure 70. Methodology
Figure 71. Research Process and Data Source
Figure 1. Nucleoside Antiviral Drugs Picture
Figure 2. World Nucleoside Antiviral Drugs Production Value: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Nucleoside Antiviral Drugs Production Value and Forecast (2021-2032) & (USD Million)
Figure 4. World Nucleoside Antiviral Drugs Production (2021-2032) & (K Dose)
Figure 5. World Nucleoside Antiviral Drugs Average Price (2021-2032) & (US$/Dose)
Figure 6. World Nucleoside Antiviral Drugs Production Value Market Share by Region (2021-2032)
Figure 7. World Nucleoside Antiviral Drugs Production Market Share by Region (2021-2032)
Figure 8. North America Nucleoside Antiviral Drugs Production (2021-2032) & (K Dose)
Figure 9. Europe Nucleoside Antiviral Drugs Production (2021-2032) & (K Dose)
Figure 10. China Nucleoside Antiviral Drugs Production (2021-2032) & (K Dose)
Figure 11. Japan Nucleoside Antiviral Drugs Production (2021-2032) & (K Dose)
Figure 12. Nucleoside Antiviral Drugs Market Drivers
Figure 13. Factors Affecting Demand
Figure 14. World Nucleoside Antiviral Drugs Consumption (2021-2032) & (K Dose)
Figure 15. World Nucleoside Antiviral Drugs Consumption Market Share by Region (2021-2032)
Figure 16. United States Nucleoside Antiviral Drugs Consumption (2021-2032) & (K Dose)
Figure 17. China Nucleoside Antiviral Drugs Consumption (2021-2032) & (K Dose)
Figure 18. Europe Nucleoside Antiviral Drugs Consumption (2021-2032) & (K Dose)
Figure 19. Japan Nucleoside Antiviral Drugs Consumption (2021-2032) & (K Dose)
Figure 20. South Korea Nucleoside Antiviral Drugs Consumption (2021-2032) & (K Dose)
Figure 21. ASEAN Nucleoside Antiviral Drugs Consumption (2021-2032) & (K Dose)
Figure 22. India Nucleoside Antiviral Drugs Consumption (2021-2032) & (K Dose)
Figure 23. Producer Shipments of Nucleoside Antiviral Drugs by Manufacturer Revenue ($MM) and Market Share (%): 2025
Figure 24. Global Four-firm Concentration Ratios (CR4) for Nucleoside Antiviral Drugs Markets in 2025
Figure 25. Global Four-firm Concentration Ratios (CR8) for Nucleoside Antiviral Drugs Markets in 2025
Figure 26. United States VS China: Nucleoside Antiviral Drugs Production Value Market Share Comparison (2021 & 2025 & 2032)
Figure 27. United States VS China: Nucleoside Antiviral Drugs Production Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Nucleoside Antiviral Drugs Consumption Market Share Comparison (2021 & 2025 & 2032)
Figure 29. United States Based Manufacturers Nucleoside Antiviral Drugs Production Market Share 2025
Figure 30. China Based Manufacturers Nucleoside Antiviral Drugs Production Market Share 2025
Figure 31. Rest of World Based Manufacturers Nucleoside Antiviral Drugs Production Market Share 2025
Figure 32. World Nucleoside Antiviral Drugs Production Value by Type, (USD Million), 2021 & 2025 & 2032
Figure 33. World Nucleoside Antiviral Drugs Production Value Market Share by Type in 2025
Figure 34. Tenofovir Alafenamide
Figure 35. Emtricitabine
Figure 36. Tenofovir Disoproxil Fumarate
Figure 37. Entecavir
Figure 38. Sofosbuvir
Figure 39. Other
Figure 40. World Nucleoside Antiviral Drugs Production Market Share by Type (2021-2032)
Figure 41. World Nucleoside Antiviral Drugs Production Value Market Share by Type (2021-2032)
Figure 42. World Nucleoside Antiviral Drugs Average Price by Type (2021-2032) & (US$/Dose)
Figure 43. World Nucleoside Antiviral Drugs Production Value by Dosage Form, (USD Million), 2021 & 2025 & 2032
Figure 44. World Nucleoside Antiviral Drugs Production Value Market Share by Dosage Form in 2025
Figure 45. Oral Solid Dosage Forms
Figure 46. Oral Liquid Dosage Forms
Figure 47. Injectable Dosage Forms
Figure 48. World Nucleoside Antiviral Drugs Production Market Share by Dosage Form (2021-2032)
Figure 49. World Nucleoside Antiviral Drugs Production Value Market Share by Dosage Form (2021-2032)
Figure 50. World Nucleoside Antiviral Drugs Average Price by Dosage Form (2021-2032) & (US$/Dose)
Figure 51. World Nucleoside Antiviral Drugs Production Value by Commercialization Status, (USD Million), 2021 & 2025 & 2032
Figure 52. World Nucleoside Antiviral Drugs Production Value Market Share by Commercialization Status in 2025
Figure 53. Originator Drugs
Figure 54. Generic Drugs
Figure 55. World Nucleoside Antiviral Drugs Production Market Share by Commercialization Status (2021-2032)
Figure 56. World Nucleoside Antiviral Drugs Production Value Market Share by Commercialization Status (2021-2032)
Figure 57. World Nucleoside Antiviral Drugs Average Price by Commercialization Status (2021-2032) & (US$/Dose)
Figure 58. World Nucleoside Antiviral Drugs Production Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 59. World Nucleoside Antiviral Drugs Production Value Market Share by Application in 2025
Figure 60. Hospital
Figure 61. Clinic
Figure 62. Other
Figure 63. World Nucleoside Antiviral Drugs Production Market Share by Application (2021-2032)
Figure 64. World Nucleoside Antiviral Drugs Production Value Market Share by Application (2021-2032)
Figure 65. World Nucleoside Antiviral Drugs Average Price by Application (2021-2032) & (US$/Dose)
Figure 66. Nucleoside Antiviral Drugs Industry Chain
Figure 67. Nucleoside Antiviral Drugs Procurement Model
Figure 68. Nucleoside Antiviral Drugs Sales Model
Figure 69. Nucleoside Antiviral Drugs Sales Channels, Direct Sales, and Distribution
Figure 70. Methodology
Figure 71. Research Process and Data Source
